Merck KGaA is looking to further boost its capacity in South Korea as biopharma companies eye to localize production and tighten their supply chains in the Asia-Pacific region.
“We go where our customers are going… APAC is now the place where we need to develop local capabilities so that we are less sensitive to all geopolitical tensions that may arise,” said Ivan Donzelot, Merck KGaA’s head of integrated supply chain operations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.